Literature DB >> 7473136

Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.

A Takagi1, H Masuda, Y Takakura, M Hashida.   

Abstract

The pharmacokinetics and disposition characteristics of recombinant human interleukin-11 (rhIL-11) after systemic administration of 10 to 1000 micrograms/kg was investigated in mice. After a bolus i.v. injection of 100 micrograms/kg of 111In-labeled rhIL-11, radioactivity disappeared rapidly from the circulation after a biexponential function. Plasma clearance profiles based on immunoreactivity and biological activity were identical to the disappearance pattern of radioactivity in the early phase after injection. In the range of 10 to 100 micrograms/kg, pharmacokinetic parameter estimates such as the T1/2 alpha and total body clearance were almost constant, suggesting that pharmacokinetics of rhIL-11 were linear within this dose range. 111In-labeled rhIL-11 distributed mainly to the kidney and liver; within 10 min, 40 and 20% of the dose, respectively, accumulated. On the other hand, the urinary excretion ratio was very small (ca., 1% of the dose), suggesting that rhIL-11 was cleared rapidly by glomeruler filtration followed by efficient tubular reabsorption. Pharmacokinetic analysis of the tissue distribution data demonstrated large kidney and hepatic uptake clearances. At the highest dose (1000 micrograms/kg), total body clearance significantly decreased, due primarily to saturation of hepatic uptake. These findings will provide useful information for the development of rhIL-11.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7473136

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  In vivo absorption properties of orally administered recombinant human interleukin-11.

Authors:  C M Tseng; L Albert; R L Peterson; P Bouchard; A J Dorner; J Keith; S P Khor
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  Pharmacokinetics and leukocyte responses of recombinant human interleukin-10.

Authors:  E Radwanski; A Chakraborty; S Van Wart; R D Huhn; D L Cutler; M B Affrime; W J Jusko
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

3.  Pharmacokinetics of [125I]-recombinant human interleukin-11: 1. Absorption, distribution and excretion after subcutaneous administration to male rats.

Authors:  T Uchida; K Aoyama; K Mori; T Usui; T Watanabe; Y Takariki; N Asahara; M Hirose; T Kimura; M Tateishi; S Higuchi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

Review 4.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

5.  Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney.

Authors:  A Takagi; Y Yabe; Y Oka; K Sawai; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

Review 6.  Pharmacokinetics of recombinant bifunctional fusion proteins.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-03-20       Impact factor: 4.481

Review 7.  Pediatric Dosing and Body Size in Biotherapeutics.

Authors:  Rong Shi; Hartmut Derendorf
Journal:  Pharmaceutics       Date:  2010-12-16       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.